Event-Driven Stocks

Transcode Therapeutics, Inc.

RNAZNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income−$28.0M−$15.7M−$19.4M−$18.6M−$6.2M−$726,604
Net income−$34.7M−$16.8M−$18.5M−$17.6M−$6.8M−$2.3M
Total assets$162.4M$7.3M$5.2M$7.6M$22.9M$1.1M
Total liabilities$10.5M$9.3M$3.5M$4.3M$2.5M$4.5M
Equity$10.3M−$2.0M$1.6M$3.2M$20.4M−$3.4M
EPS (diluted)$-52.59$-47.14$-3419.01$-1082.79$-0.81$-0.51
Shares out.23.3M5.8M15.8M12.9M12.9M4.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−335.4%
Return on assets
−21.3%
Return on capital (ROCE)
−17.6%
Liabilities / assets
6.5%
Debt / equity
1.02×
Book value / share
$0.44
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-1.34distress
Accruals / assets
−9.3%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
61
/ 100
Profitability 0Growth n/aCatalyst 100Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
4 acquisitions0 disposals4 open-market buy(s)net +172,957 shares · last 4
InsiderDateTypeSharesPrice
Fitzgerald Thomas AOfficer — Chief Financial OfficerSep 28, 2023Buy49,350$0.51
Dudley Robert MichaelOfficer — Chief Executive OfficerSep 28, 2023Buy98,000$0.51
Dudley Robert MichaelOfficer — Chief Executive OfficerJun 20, 2023Buy6,607$2.55
Dudley Robert MichaelOfficer — Chief Executive OfficerJun 9, 2023Buy19,000$2.76

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202636,2654.1+1.4%
Apr 30, 202635,7577.6-12.9%
Apr 15, 202641,0716.4-17.8%
Mar 31, 202649,9766.1-26.9%
Mar 13, 202668,3345.4-11.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.